In particular, during the Track Record Period, GYMCL Related Parties were our limited source of suppliers for components such as cylinder block rough castings, cylinder head rough castings and cylinder blocks for certain specific engine series, and we procured substantially all such components primarily from them.
Business · p. 148
Our Directors are of the view that this arrangement will not affect the operations of our business because we have maintained a good and stable relationship with GYMCL Related Parties, and the risk of GYMCL Related Parties terminating the supply of such components to us is remote.
Business · p. 148
In addition, according to Frost & Sullivan, there are other alternative suppliers in the market which can supply comparable components in comparable quantities.
The brands we use in our private-label pharmaceutical business, such as “Shu Han Ben Cao (蜀漢本草)”, “Fu Xin (芙新)”, “Gu Fang Xuan Hu (古方懸壺)”, “Chi Ming (馳銘)” and “Hao Jian Shan (好健膳)” are owned by us or licensed exclusively to us by Sichuan JND and its subsidiaries through an exclusive licence, and typically presented side-by-side with the “Good Doctor” trademark (“ ”) owned by Sichuan JND’s subsidiary and licensed for our use.
We have one Core Product and two other pipeline drug candidates, all of which were in-licensed from our collaboration partner and one of the Controlling Shareholders, Ascendis Pharma.
Summary · p. 1
We expect to procure the Core Product from Ascendis Pharma for the commercial supply until 2028 following our anticipated commercialization activities in late 2025 after BLA approval.
Summary · p. 7
The interests of Ascendis Pharma are highly aligned with ours.